|1.||Driessen, J J: 7 articles (07/2011 - 01/2000)|
|2.||Platt, P R: 4 articles (11/2015 - 02/2011)|
|3.||Turan, Alparslan: 4 articles (08/2015 - 06/2002)|
|4.||Raft, J: 4 articles (11/2014 - 02/2012)|
|5.||Meistelman, C: 4 articles (06/2014 - 09/2009)|
|6.||Driessen, Jacques J: 4 articles (04/2011 - 07/2002)|
|7.||Robertson, E N: 4 articles (06/2010 - 01/2000)|
|8.||Mencke, T: 4 articles (04/2009 - 09/2001)|
|9.||Forst, Juergen: 4 articles (02/2009 - 05/2005)|
|10.||Muenster, Tino: 4 articles (02/2009 - 05/2005)|
02/01/2013 - "Rocuronium was then administered and patients were asked to report their pain Compared to control group, all pretreatment drugs were effective in reducing pain on rocuronium injection. "
02/01/2013 - "Comparison of three methods of preventing rocuronium induced pain on injection using venous occlusion technique: a randomized prospective double blind controlled study."
12/01/2010 - "In a prospective randomized study, we evaluated whether pretreatment with local warming at injection site using an air-warming device could effectively alleviate pain induced by rocuronium. "
09/01/2007 - "Neutralized rocuronium (pH 7.4) before administration prevents injection pain in awake patients: a randomized prospective trial."
11/01/2004 - "The purpose of this study was to investigate whether gender influences the perception of pain on injection of rocuronium. "
|2.||Anaphylaxis (Anaphylactic Shock)
04/01/2015 - "Contraindications to rocuronium use included high probability of difficult airway and anaphylaxis. "
01/01/2015 - "Previous reports suggest that the rates of anaphylaxis may be greater for rocuronium than for other NMBDs, but imprecise surrogate metrics for new patient exposures to NMBDs complicate interpretation. "
01/01/2014 - "[Rocuronium-induced anaphylaxis. "
10/01/2013 - "The laboratory data showed a marked increase in vascular permeability caused by rocuronium-induced anaphylactic shock."
10/01/2013 - "We report a case of a 19-year-old male with rocuronium-induced anaphylactic shock. "
06/01/2014 - "Precurarization with 0.04 mg/kg rocuronium was the optimal dose considering the reduction in the incidence and severity of fasciculation and myalgia with acceptable onset time, and the safe and effective precurarization."
06/01/2014 - "The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of rocuronium (P < 0.001). "
12/01/2009 - "It is concluded that pretreatment with Rocuronium reduced the incidence of myalgias, fasciculations and produced rapid precurarization in one minute thereby saving time on busy operating lists. "
06/01/1998 - "Muscle fasciculations were observed in 19 of the 20 patients in the control group and in 3 of the 20 patients in the rocuronium group, the best of the pretreatments in that aspect. "
12/01/1999 - "Rocuronium pretreatment was more effective in reducing fasciculations than was vecuronium pretreatment, but both were equally effective in preventing myalgia on postoperative day 1. This difference may reflect the differential activities of rocuronium and vecuronium at the neuromuscular junction. "
08/01/2001 - "To evaluate the safety and efficacy of rocuronium for controlled intubation with paralysis (CIP) in the pediatric ED. "
06/01/2002 - "Further study of rocuronium's potential as an intraoperative pharmacodynamic probe of liver function by measuring neuromuscular paralysis is suggested."
09/01/2012 - "Total, oral, and nasal tidal volumes did not significantly change at complete muscle paralysis with rocuronium. "
07/01/2012 - "[Prolonged residual paralysis after a single intubating dose of rocuronium: an unexpected cause]."
12/01/2011 - "Because of the large variation in the recovery from rocuronium-induced paralysis, TOF-based evaluation of residual paralysis is essential to determine the appropriate indication for reversal, especially for elderly patients."
|5.||Renal Insufficiency (Renal Failure)
01/01/2005 - "This increase may be due to a decreased clearance of rocuronium, the disease process causing the renal failure and/or the medication which patients with renal failure need in their treatment."
01/01/2005 - "Clearance of rocuronium was reduced by 39% in the renal failure patients compared to control, with an 84% increase in the mean residence time. "
01/01/2005 - "This study clarifies the relationship between the neuromuscular blocking effects of rocuronium 0.6 mg kg(-1) and its pharmacokinetics in patients with renal failure. "
01/01/2013 - "An important lesson to recognise is the potential for extremely prolonged neuromuscular blockade following rocuronium in patients with severe renal failure, particularly when using the higher doses (1.2 mg/kg) required for RSI, and that TOF in such cases may not be reliable in detecting residual blockade."
01/01/2013 - "We describe our experience of a 71-year-old patient with severe renal failure, who exhibited an unusually prolonged rocuronium-induced neuromuscular blockade (>4 h) and apparent recurarisation, following emergency rapid sequence induction (RSI). "
|3.||Succinylcholine (Suxamethonium Chloride)
|8.||Sodium Bicarbonate (Baking Soda)
|10.||Vecuronium Bromide (Vecuronium)
|3.||Ambulatory Surgical Procedures (Outpatient Surgery)